AGL:LSE-ANGLE plc (GBX)

COMMON STOCK | Diagnostics & Research | LSE

Last Closing Price

GBX 132.00

Change

0.00 (0.00)%

Market Cap

GBX 0.31B

Volume

0.90M

Avg Analyst Target

N/A

Avg User Target

GBX
Average Analyst Rating

N/A

Fundamental Analysis

Verdict


ANGLE plc (AGL) Stock Analysis:
Based on the ANGLE plc stock forecasts from 0 analysts, the average analyst target price for ANGLE plc is not available over the next 12 months. ANGLE plc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of ANGLE plc is Bearish, which is based on 1 positive signals and 4 negative signals. At the last closing, ANGLE plc’s stock price was GBX 132.00. ANGLE plc’s stock price has changed by -3.00 % over the past week, +13.00 % over the past month and +225.93 % over the last year.

About

ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products worldwide. The company develops and commercializes Parsortix cell separation system, which captures and harvests circulating tumor cells in cancer patient blood; and HyCEAD multiplex analys ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-11-28 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MXCL:LSE MaxCyte, Inc

N/A

GBX0.86B N/A N/A
IDHC:LSE Integrated Diagnostics Holding..

N/A

GBX0.77B 7.74 0.27
MXCT:LSE MaxCyte Inc

N/A

GBX0.72B N/A N/A
RENX:LSE Renalytix Plc

N/A

GBX0.50B N/A N/A
NCYT:LSE Novacyt S.A

N/A

GBX0.31B 3.63 1.23
HZD:LSE Horizon Discovery Group plc

N/A

GBX0.30B N/A N/A
GENI:LSE Genincode PLC

N/A

GBX0.04B N/A N/A
ABDX:LSE Abingdon Health Plc

N/A

GBX0.04B N/A 104.75
GDR:LSE genedrive plc

N/A

GBX0.02B N/A N/A
PRM:LSE Proteome Sciences plc

N/A

GBX0.02B 55.00 33.82

ETFs Containing AGL

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Diagnostics & Research)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 176.44% 100% A+ 98% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 176.44% 100% A+ 98% A+
Trailing 12 Months  
Capital Gain 225.93% 100% A+ 99% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 225.93% 100% A+ 99% A+
Trailing 5 Years  
Capital Gain 109.52% 83% B 87% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 109.52% 67% D+ 85% B
Average Annual (5 Year Horizon)  
Capital Gain 27.23% 50% F 82% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 27.23% 38% F 80% B-
Risk Return Profile  
Volatility (Standard Deviation) 50.80% 75% C 27% F
Risk Adjusted Return 53.60% 63% D 66% D
Market Capitalization 0.31B 67% D+ 49% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Diagnostics & Research)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 11.51 25% F 6% F
Price / Cash Flow Ratio -39.54 89% B+ 92% A-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -59.70% 43% F 6% F
Return on Invested Capital -60.81% 22% F 5% F
Return on Assets -32.77% 38% F 3% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.64 50% F 79% C+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (GBX)

Quarterly Financials (GBX)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector